Skip to main content
SpringerLink
Log in

Hyperthyroidism

  • Chapter
Early Diagnosis and Treatment of Endocrine Disorders

Part of the book series: Contemporary Endocrinology ((COE))

  • 148 Accesses

Abstract

The introduction of increasingly sensitive serum thyroid-stimulating hormone (TSH) assays over the past decade has led to the ability to detect thyrotoxicosis at an early stage, before the development of overt disease. TSH screening is now widely advocated for some groups of asymptomatic patients. The clinical consequences of subclinical thyrotoxicosis are becoming better understood, but the best method for the workup and treatment of subclinical disease remains controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Laurberg P, Bulow Pedersen I, Knudsen N, Ovesen L, Andersen S. Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid 2001;11:457–469.

    Article  PubMed  CAS  Google Scholar 

  2. Samuels MH. Subclinical thyroid disease in the elderly. Thyroid 1998;8:803–813.

    Article  PubMed  CAS  Google Scholar 

  3. Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: The Whickham Survey. Clin Endocrinol 1977;7:481–493.

    Article  CAS  Google Scholar 

  4. Vanderpump PJ, Tunbridge WMG. The epidemiology of thyroid diseases. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid, 8th ed. JB Lippincott, Philadelphia, 2000, pp. 467–473.

    Google Scholar 

  5. Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years: a study in an urban US community. Arch Intern Med 1990;150:785–787.

    Article  PubMed  CAS  Google Scholar 

  6. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med 2000;160:526–534.

    Article  PubMed  CAS  Google Scholar 

  7. Hollowell JG, Staehling NW, Hannon WH, et al. Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab, 2002;87:489–499.

    Article  PubMed  CAS  Google Scholar 

  8. Surks MI, Chopra IJ, Mariash CN, et al. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 1990;263:1529–1532.

    Article  PubMed  CAS  Google Scholar 

  9. US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Williams & Wilkins, Baltimore, 1996.

    Google Scholar 

  10. Helfand M, Redfern CC. Screening for thyroid disease: an update. Ann Intern Med 1998;129:144–158.

    PubMed  CAS  Google Scholar 

  11. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000;160:1573–1575.

    Article  PubMed  CAS  Google Scholar 

  12. Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA 1996;276:285–292.

    Article  PubMed  CAS  Google Scholar 

  13. Ladenson PW. Thyrotoxicosis and the heart: something old and something new. J Clin Endocrinol Metab 1993;77:332–333.

    Article  PubMed  CAS  Google Scholar 

  14. Sulimani RA. Diagnostic algorithm for atrial fibrillation caused by occult hyperthyroidism. Geriatrics 1989;44:61–64.

    PubMed  CAS  Google Scholar 

  15. Sawin CT, Geller A, Kaplan MM, Bacharach P, Wilson PWF, Hershman JM. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 1991;151:165–168.

    Article  PubMed  CAS  Google Scholar 

  16. Surks MI, Ocampo E. Subclinical thyroid disease. Am J Med 1996;100:217–223.

    Article  PubMed  CAS  Google Scholar 

  17. McDougall IR, Cavalieri RR. In vivo radionuclide tests and imaging. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid, 8th ed. JB Lippincott, Philadelphia, 2000, pp. 355–375.

    Google Scholar 

  18. Marcocci C, Chiovato L. Thyroid-directed antibodies. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’ s The Thyroid, 8th ed. JB Lippincott, Philadelphia, 2000, pp. 414–431.

    Google Scholar 

  19. Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 1990;89:602–608.

    Article  PubMed  CAS  Google Scholar 

  20. Denham MJ, Wills EJ. A clinico-pathological survey of thyroid glands in old age. Gerontology 1980;26:160–166.

    Article  PubMed  CAS  Google Scholar 

  21. Pullen R, Hintze G. Size and structure of the thyroid in old age. J Am Geriatr Soc 1997;5:1539.

    Google Scholar 

  22. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001;22:240–254.

    Article  PubMed  CAS  Google Scholar 

  23. Mokshagundam S, Barzel US. Thyroid disease in the elderly. J Am Geriatr Soc 1993;41:1361–1369.

    PubMed  CAS  Google Scholar 

  24. Charkes ND. The many causes of subclinical hyperthyroidism. Thyroid 1996;6:391–396.

    Article  PubMed  CAS  Google Scholar 

  25. Krassas GE, Pontikides N, Kaltsas T, et al. Menstrual disturbances in thyrotoxicosis. Clin Endocrinol 1994;40:641–644.

    Article  CAS  Google Scholar 

  26. Whybrow PC, Bauer M. Behavioral and psychiatric aspects of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid, 8th ed. JB Lippincott, Philadelphia, 2000, pp. 673–678.

    Google Scholar 

  27. Schlote-Sautter B, Schmidt R, Kaumeier S, Teuber J, Vardarli I, Usaldel KH. Subclinical hyperthyroidism: do physical and mental symptoms exist that justify treatment? In: Reinwein D, Scriba PC, eds. The Various Types of Hyperthyroidism. Urban & Schwartzenberg, Munich, 1990, 319–322.

    Google Scholar 

  28. Braverman LE, Utiger RD. Introduction to thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid, 8th ed. JB Lippincott, Philadelphia, 2000, pp. 515–517.

    Google Scholar 

  29. Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years: clinical features in 85 patients. Medicine 1974;53:161–181.

    Article  PubMed  CAS  Google Scholar 

  30. Bahn RS, Heufelder AE. Mechanisms of disease: pathogenesis of Graves’ ophthalmopathy. N Engl J Med 1993;329:1468–1475.

    Article  PubMed  CAS  Google Scholar 

  31. Marnini P, Piantanida E, Venco A. Hyperthyroidism in the elderly: difference in the clinical findings compared with younger patients. J Endocrinol Invest 1999;22 (suppl to no. 10):44.

    PubMed  CAS  Google Scholar 

  32. Nordyke RA, Gilbert FI, Harada AS. Graves’ disease: influence of age on clinical findings. Arch Intern Med 1988;148:626–631.

    Article  PubMed  CAS  Google Scholar 

  33. Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996;44:50–53.

    PubMed  CAS  Google Scholar 

  34. Lahey FH. Nonactivated (apathetic) type of hyperthyroidism. N Engl J Med 1931;204:747–748.

    Article  Google Scholar 

  35. Jayme JJ, Ladenson PW. Subclinical thyroid dysfunction in the elderly. Trends Endocrinol Metab 1994;5:79–86.

    Article  PubMed  CAS  Google Scholar 

  36. Sirota DK. Thyroid function and dysfunction in the elderly: a brief review. Mt Sinai J Med 1980;47:126–131.

    PubMed  CAS  Google Scholar 

  37. Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986;314:1676–1686.

    Article  PubMed  CAS  Google Scholar 

  38. Wasnich RD. Epidemiology of osteoporosis. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th ed. Lippincott, Philadelphia, 1999, pp. 257–259.

    Google Scholar 

  39. Baran DT, Braverman LE. Editorial: thyroid hormones and bone mass. J Clin Endocrinol Metab 1991;72:1182–1183.

    Article  PubMed  CAS  Google Scholar 

  40. Harvey RD, McHardy KC, Reid IW, et al. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991;72:1189–1194.

    Article  PubMed  CAS  Google Scholar 

  41. Burman KD, Monchik JM, Earll JM, Wartofsky L. Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann Intern Med 1976;84:668–671.

    PubMed  CAS  Google Scholar 

  42. Lee MS, Kim SY, Lee MC, et al. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 1990;70:766–770.

    Article  PubMed  CAS  Google Scholar 

  43. Ross DS. Hyperthyroidism, thyroid hormone therapy and bone. Thyroid 1994;4:319–326.

    Article  PubMed  CAS  Google Scholar 

  44. Ross DS, Neer RM, Ridgway RC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with Lthyroxine. Am J Med 1987;82:1167–1170.

    Article  PubMed  CAS  Google Scholar 

  45. Grant DJ, McMurdo MET, Mole PA, Paterson CR, Davies RR. Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin Endocrinol 1993;39:529–533.

    Article  CAS  Google Scholar 

  46. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women: effects of estrogen. JAMA 1994;271:1245–1249.

    Article  PubMed  CAS  Google Scholar 

  47. Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H. determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol 1992;36:511–517.

    Article  CAS  Google Scholar 

  48. Kung AWC, Lorentz T, Tam SCF. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol 1993;39:535–540.

    Article  CAS  Google Scholar 

  49. Campbell J, Day P, Diamond T. Fine adjustments in thyroxine replacement and its effect on bone metabolism. Thyroid 1996;6:75–78.

    Article  PubMed  CAS  Google Scholar 

  50. Hanna FWF, Pettit RJ, Ammari F, Evans WD, Sandeman D, Lazarus JH. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol 1998;48:229–234.

    Article  CAS  Google Scholar 

  51. Gou CY, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 1997;46:301–307.

    Article  Google Scholar 

  52. Mudde AH, Reijnders FJL, Kruseman CAN. Peripheral bone density in women with untreated multinodular goiter. Clin Endocrinol 1992;37:35–39.

    Article  CAS  Google Scholar 

  53. Leese GP, Jung RT, Guthrie C, Waugh N, Browning MCK. Morbidity in patients on Lthyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol 1992;37:500–503.

    Article  CAS  Google Scholar 

  54. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001;134:561–568.

    PubMed  CAS  Google Scholar 

  55. Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 1997;12:72–77.

    Article  PubMed  CAS  Google Scholar 

  56. Lecomte P, Lecureuil N, Osorio-Salazar C, Lecureuil M, Valat C. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism. Thyroid 1995;5:19–23.

    Article  PubMed  CAS  Google Scholar 

  57. Foldes J, Tarjan G, Szathmari M, Varga F, Kresznal I, Horvath C. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol 1993;39:521–527.

    Article  CAS  Google Scholar 

  58. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999;9:539–543.

    Article  PubMed  CAS  Google Scholar 

  59. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT. Long-term 1-thyroxine therapy is associated with decreased hip bone density in pre-menopausal women. JAMA 1988;259:3137–3141.

    Article  PubMed  CAS  Google Scholar 

  60. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81:4278–4289.

    Article  PubMed  CAS  Google Scholar 

  61. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350–356.

    Article  PubMed  CAS  Google Scholar 

  62. Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998;83:2324–2330.

    Article  PubMed  CAS  Google Scholar 

  63. Kahaly GJ, Nieswandt J, Mohr-Kahaly S. Cardiac risks of hyperthyroidism in the elderly. Thyroid 1998;8:1165–1169.

    Article  PubMed  CAS  Google Scholar 

  64. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501–509.

    Article  PubMed  CAS  Google Scholar 

  65. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin-suppressive therapy with thyroxine. J Clin Endocrinol Metab 1996;81:4224–4228.

    Article  PubMed  CAS  Google Scholar 

  66. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with thyroxine. J Clin Endocrinol Metab 1993;77:334–338.

    Article  PubMed  CAS  Google Scholar 

  67. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 1997;82:2592–2595.

    Article  PubMed  CAS  Google Scholar 

  68. Tenerz A, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med 1990;228:229–233.

    Article  PubMed  CAS  Google Scholar 

  69. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249–1252.

    Article  PubMed  CAS  Google Scholar 

  70. Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid, 8th ed. JB Lippincott, Philadelphia, 2000, pp. 691–715.

    Google Scholar 

  71. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 1995;273:808–812.

    Article  PubMed  CAS  Google Scholar 

  72. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves’ hyperthyroidism. J Clin Endocrinol Metab 1999;84:4012–4016.

    Article  PubMed  CAS  Google Scholar 

  73. Burch HB, Solomon BL, Wartofsky L, et al. Discontinuing antithyroid drug therapy before ablation with radioactive iodine in Graves’ disease. Ann Intern Med 1994;121:553–559.

    PubMed  CAS  Google Scholar 

  74. Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol 1991;35:439–442.

    Article  CAS  Google Scholar 

  75. Nakazawa HK, Sakurai K, Hamada N. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982;72:903–906.

    Article  PubMed  CAS  Google Scholar 

  76. Koutras DA. Subclinical hyperthyroidism.Thyroid 1999;9:311–315.

    Article  PubMed  CAS  Google Scholar 

  77. Ross DS. Subclinical thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’ s The Thyroid, 8th ed. JB Lippincott, Philadelphia, 2000, pp. 1007–1012.

    Google Scholar 

  78. Huysmans DA, Nieuwlatt WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000;85:3592–3596.

    Article  PubMed  CAS  Google Scholar 

  79. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001;86:1660–1664.

    Article  PubMed  CAS  Google Scholar 

  80. Toft AD. Clinical practice: subclinical hyperthyroidism. N Engl J Med 2001;345:512–516.

    Article  PubMed  CAS  Google Scholar 

  81. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol 1998;48:285–290.

    Article  CAS  Google Scholar 

  82. Mudde AH, Houben AJHM, Kruseman CAN. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol 1994;41:421–424.

    Article  CAS  Google Scholar 

  83. Utiger RD. Subclinical hyperthyroidism just a low serum thyrotropin concentration, or something more? N Engl J Med 1994;331:1302–1303.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Elizabeth N. Pearce MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lewis E. Braverman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology and Metabolism Department of Internal Medicine, The University of Iowa School of Medicine, Iowa City, IA, USA

    Robert S. Bar MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pearce, E.N., Braverman, L.E. (2003). Hyperthyroidism. In: Bar, R.S. (eds) Early Diagnosis and Treatment of Endocrine Disorders. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-378-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-378-1_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-414-2

  • Online ISBN: 978-1-59259-378-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation